Status:
UNKNOWN
Combined Intralesional Triamcinolone Injection With Whole Breast Detection Radical Surgery
Lead Sponsor:
Wuhan University
Conditions:
Refractory Granulomatous Lobular Mastitis
Eligibility:
FEMALE
18-60 years
Phase:
NA
Brief Summary
Granulomatous lobular mastitis (GLM) is a rare, chronic benign inflammatory disease of the breast, of unknown etiology. Pathologically, GLM typically manifests as non-caseating granulomatous lesions w...
Eligibility Criteria
Inclusion
- Patients who were pathologically diagnosed as refractory granulomatous lobular mastitis.
- Lesions are extensively distributed to more than three quadrants or with abscesses, sinus, fistula and persistent wound infection (skin ulceration and pus).
- Patients voluntarily participate in studies with informed consent.
Exclusion
- History of breast surgery.
- Patients who choose conservative treatment.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05281419
Start Date
May 1 2022
End Date
December 31 2024
Last Update
March 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qianqian Yuan
Wuhan, Hubei, China, 430071